PCVX: financial statements from SEC — TradeAlmanac

PCVX

Vaxcyte, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Research and development	313m	210m	194m	148m	117m	132m
Selling, general and administrative	33m	32m	32m	33m	23m	21m
Operating expenses	346m	242m	226m	181m	140m	153m
Operating income	−346m	−242m	−226m	−181m	−140m	−153m
Net income	−321m	−213m	−167m	−141m	−103m	−129m
Earnings per share	−2.30	−1.56	−1.22	−1.04	−0.83	−1.10
Earnings per share, diluted	−2.30	−1.56	−1.22	−1.04	−0.83	−1.10
Weighted average shares	140m	136m	136m	136m	124m	117m
Weighted average shares, diluted	140m	136m	136m	136m	124m	117m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	261m	174m	281m	307m	347m	388m	1.05bn	519m
Short-term investments	1.48bn	1.39bn

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−281m	−166m
Depreciation and amortisation	3m	3m
Share-based compensation	38m	31m
Capital expenditure	2m	5m
Investing cash flow	−233m	123m
Financing cash flow	602m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)